You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

non-small cell lung carcinoma (NSCLC)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Apr 21, 2023

    Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy Trial in Wuhan (CTV omitted or delineated)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • CTV omitted or delineated
    • Wuhan, Hubei, China
      Hubei Cancer Hospital
    Sep 1, 2023

    NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Feb 22, 2023

    Non Small Cell Lung Cancer Trial in Leiden, Rotterdam (TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51))

    Recruiting
    • Non Small Cell Lung Cancer
    • TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)
    • Leiden, Zuid-Holland, Netherlands
    • +1 more
    Jun 1, 2023

    NSCLC Trial in Shanghai (WX-0593)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Shanghai, China
      Shanghai Jiao Tong University Chest Hospital
    Mar 24, 2023

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    NSCLC, NSCLC Stage IV, NSCLC Stage IIIB Trial (MYTX-011)

    Not yet recruiting
    • NSCLC
    • +5 more
    • (no location specified)
    Dec 7, 2022

    NSCLC Trial (TAS3351 oral administration)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • TAS3351 oral administration
    • (no location specified)
    Mar 8, 2023

    Omitting Clinical Target Volume in Radical Treatment of

    Not yet recruiting
    • Immunotherapy
    • +3 more
    • IMRT+adjuvant immunotherapy
    • (no location specified)
    Jun 9, 2023

    NSCLC Trial in Liège (induced sputum, lung biopsy, bronchoalveolar lavage)

    Recruiting
    • Non-small Cell Lung Cancer
    • induced sputum
    • +3 more
    • Liège, Belgium
      CHU de Liège
    Nov 7, 2022

    NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

    Not yet recruiting
    • Non-Small Cell Lung Cancer(NSCLC)
    • WX-0593 Tablets
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Mar 1, 2023

    Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

    Not yet recruiting
    • Lung Cancer
    • Non-small Cell Lung Cancer
    • (no location specified)
    Jul 7, 2023

    NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Cancer Center
    May 22, 2023

    Non Small Cell Lung Cancer Trial (TGRX-326, Crizotinib)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • (no location specified)
    Oct 8, 2023

    NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Fairfax, Virginia
      NEXT Virginia
    Sep 18, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    NSCLC Trial (Dupilumab, Cemiplimab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Dupilumab
    • Cemiplimab
    • (no location specified)
    Oct 12, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    Results of Specific Gene Testing and Efficacy of Targeted

    Completed
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Mar 27, 2023

      Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

      Not yet recruiting
      • Non Squamous Non Small Cell Lung Cancer
      • EGFR Positive Non-small Cell Lung Cancer
      • Toripalimab plus Chemotherapy
      • (no location specified)
      Jul 28, 2023

      Locally Advanced or Metastatic NSCLC Trial (HB1801, Taxotere)

      Not yet recruiting
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • (no location specified)
      May 8, 2023

      NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

      Recruiting
      • NSCLC
      • PEF
      • Anti-PD-1 monoclonal antibody
      • Guangzhou, Guangdong, China
        The first Affiliated Hospital of Guangzhou Medical University
      Aug 3, 2023

      NSCLC Trial in Guangzhou (PLB1001)

      Active, not recruiting
      • Non-small Cell Lung Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Aug 15, 2023

      Circulating Tumor DNA and T Cell Repertoire Predict

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Brain Metastases
      • Whole-brain radiotherapy
      • Wuhan, Hubei, China
        Union hospital
      Feb 12, 2023